Table 1.
Summarized data regarding the efficacy/ineffective effects of probiotics in GI diseases.
Gastrointestinal Diseases/Disorders | Effect of Probiotics | Reference |
---|---|---|
Efficacy of probiotics in gastrointestinal diseases | ||
Acute Bacterial Infectious Diarrhea | ↓duration of the disease, ↓the risk of prolongation over four days | [28] |
↓ the number of daily stools | ||
Traveler’s diarrhea | preventive effect | [29] |
Acute viral diarrhea | no significant difference between the group of patients who received the probiotic containing Lactobacillus rhamnosus GG and the control group | [30] |
Diarrhea associated with antibiotic therapy | prevents or lessens the course of diarrhea | [33,34] |
↓stool frequency, ↑recovery, ↓disease duration | [40] | |
Helicobacter pylori Infection | adjunct to antibiotic therapy to eradicate Helicobacter pylori infection | [41] |
Ulcerative Colitis, Irritable Bowel Syndrome, Functional Abdominal Pain | it cannot be concluded whether the use of probiotics has a general benefit in the evolution of these diseases. | [43] |
↑remission rate in adults with ulcerative colitis, not maintaining remission, ↓symptoms, ↑ quality of life | [45] | |
Chronic Constipation | ↑ average number of stools per week | [46] |
Necrotizing Enterocolitis | ↓the risk of severe necrotizing enterocolitis, ↓ mortality | [47] |
Hepatic encephalopathy | ↓ risk of developing hepatic encephalopathy | [48] |
Nonalcoholic Steatohepatitis | ↑liver function | [49] |
Celiac Diseases, Non-celiac Gluten Sensitivity, Food Allergy | ↑protection from gluten-induced pathology | [56] |
↑protection against peanut allergy | [60] | |
↑ immune reactions, ↑levels of antibodies | [61] | |
Symptomatic uncomplicated diverticular disease | the therapeutic effect is not fully known | [66] |
Ineffectiveness of probiotics in gastro-intestinal disease | ||
Pancreatitis | Ineffective | [67] |
Crohn’s disease | Insufficient evidence |
Symbols: ↑ (increased), ↓ (decreased).